Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

ABSTRACT: Skull base chordomas are challenging tumors due to their deep surgical location and resistance to conventional radiotherapy. Chemotherapy plays a marginal role in the treatment of chordoma resulting from lack of preclinical models due to the difficulty in establishing tumor cell lines and valuable in vivo models. Here, we established a cell line from a recurrent clival chordoma. Cells were cultured for more than 30 passages and the expression of the chordoma cell marker brachyury was monitored using both immunohistochemistry and Western blot. Sensitivity of chordoma cells to the inhibition of specific signaling pathways was assessed through testing of a commercially available small molecule kinase inhibitor library. In vivo tumorigenicity was evaluated by grafting chordoma cells onto immun

SUBMITTER: Ricci-Vitiani L 

PROVIDER: S-EPMC3689240 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature